Identification

Name
Xylometazoline
Accession Number
DB06694
Type
Small Molecule
Groups
Approved
Description

A nasal vasoconstricting decongestant drug which acts by binding to the same receptors as adrenaline. It is applied as a spray or as drops into the nose to ease inflammation and congestion of the nasal passageways. It binds alpha-adrenergic receptors to activate the adrenal system which causes systemic vasoconstriction, thereby easing nasal congestion.

Structure
Thumb
Synonyms
  • Balminil
  • Xylomethazoline
Product Ingredients
IngredientUNIICASInChI Key
Xylometazoline hydrochlorideX5S84033NZ1218-35-5YGWFCQYETHJKNX-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
4 Way Moisturizing ReliefSpray.01 L/LNasalNovartis2010-01-012017-08-19Us
Aqua Maris Fast Acting DecongestantSpray10 mg/10mLNasalJgl North America Llc2012-12-15Not applicableUs
Aqua Maris Kids Fast Acting DecongestantSpray.05 mg/10mLNasalJgl North America Llc2010-09-27Not applicableUs
Balminil DecongestSolution0.1 %NasalTeva2007-12-14Not applicableCanada
Balminil Nasal DecongestantSpray0.1 %NasalTeva1997-08-26Not applicableCanada
Certified Decongestant Nasal Spray .1%Solution; Spray0.1 %NasalProdemdis Enr.1996-09-192010-07-15Canada
Cold & Allergy ReliefSpray0.1 %NasalPharmascience Inc2003-02-01Not applicableCanada
Cold & Allergy Relief With MoisturizersSpray0.1 %NasalPharmascience Inc2003-02-01Not applicableCanada
Cold and Allergy Decongestant Nasal SpraySpray0.1 %NasalTeva2011-10-01Not applicableCanada
Decongest NasalSolution0.1 %NasalTeva2007-12-20Not applicableCanada
International/Other Brands
Otriven / Otrivin / Otrivine / Otrix / Xylomet / Xylostar (Intas)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ophtrivin A Ophthalmic DpsXylometazoline hydrochloride (.05 %) + Antazoline sulfate (.5 %)Solution / dropsOphthalmicCiba Vision1992-12-312000-11-08Canada
Categories
UNII
WPY40FTH8K
CAS number
526-36-3
Weight
Average: 244.3752
Monoisotopic: 244.193948778
Chemical Formula
C16H24N2
InChI Key
HUCJFAOMUPXHDK-UHFFFAOYSA-N
InChI
InChI=1S/C16H24N2/c1-11-8-13(16(3,4)5)9-12(2)14(11)10-15-17-6-7-18-15/h8-9H,6-7,10H2,1-5H3,(H,17,18)
IUPAC Name
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole
SMILES
CC1=CC(=CC(C)=C1CC1=NCCN1)C(C)(C)C

Pharmacology

Indication

It is used for treating nasal congestion and minor inflammation due to allergies or colds.

Structured Indications
Pharmacodynamics

Xylometazoline is a direct acting sympathomimetic adrenergic alpha-agonist used to induce systemic vasoconstriction, thereby decreasing nasal congestion. The sympathomimetic action of xylometazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (8-12 hours) decongesting effect.

Mechanism of action

Xylometazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
agonist
Human
AAlpha-2A adrenergic receptor
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
UAlpha-1B adrenergic receptor
agonist
Human
UAlpha-1D adrenergic receptor
agonist
Human
UAlpha-2C adrenergic receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Xylometazoline.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Xylometazoline.Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Xylometazoline.Experimental
AcebutololXylometazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcemetacinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
AliskirenXylometazoline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmbrisentanXylometazoline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineXylometazoline may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineAmineptine may decrease the antihypertensive activities of Xylometazoline.Illicit, Withdrawn
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Xylometazoline.Approved
AmobarbitalThe metabolism of Xylometazoline can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Xylometazoline.Approved, Investigational
AmoxapineAmoxapine may decrease the antihypertensive activities of Xylometazoline.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Xylometazoline.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Xylometazoline.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Xylometazoline.Approved, Investigational
ArotinololXylometazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Xylometazoline.Approved
AtenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Atosiban.Approved, Investigational
Atracurium besylateXylometazoline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Xylometazoline.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Xylometazoline.Experimental
BarbexacloneThe metabolism of Xylometazoline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Xylometazoline can be increased when combined with Barbital.Illicit
BarnidipineXylometazoline may increase the antihypertensive activities of Barnidipine.Approved
BefunololXylometazoline may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenazeprilBenazepril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Xylometazoline.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Xylometazoline.Approved
BepridilBepridil may increase the hypotensive activities of Xylometazoline.Approved, Withdrawn
BetaxololXylometazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BethanidineBethanidine may increase the hypotensive activities of Xylometazoline.Approved
BevantololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Xylometazoline.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Xylometazoline.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BisoprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BosentanBosentan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
BQ-123Xylometazoline may increase the hypotensive activities of BQ-123.Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Xylometazoline.Experimental
BretyliumBretylium may increase the hypotensive activities of Xylometazoline.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Xylometazoline.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Xylometazoline.Experimental
BucindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolXylometazoline may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BunazosinBunazosin may increase the hypotensive activities of Xylometazoline.Investigational
BupranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Xylometazoline.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Xylometazoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Xylometazoline.Experimental
CafedrineXylometazoline may increase the hypotensive activities of Cafedrine.Investigational
Calcium AcetateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanXylometazoline may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Xylometazoline.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Xylometazoline.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Xylometazoline.Experimental
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Xylometazoline.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Xylometazoline.Approved
CarbomycinThe metabolism of Xylometazoline can be decreased when combined with Carbomycin.Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Xylometazoline.Withdrawn
CarteololXylometazoline may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolXylometazoline may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CaseinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Xylometazoline.Approved
CeliprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Xylometazoline.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Xylometazoline.Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Xylometazoline.Approved
CicletanineXylometazoline may increase the hypotensive activities of Cicletanine.Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Xylometazoline.Approved, Investigational
CilazaprilCilazapril may increase the hypotensive activities of Xylometazoline.Approved
CimetidineThe serum concentration of Xylometazoline can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Xylometazoline can be decreased when combined with Clarithromycin.Approved
ClomipramineClomipramine may decrease the antihypertensive activities of Xylometazoline.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Xylometazoline.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Xylometazoline.Approved
CloranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Xylometazoline.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Xylometazoline.Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Xylometazoline.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Xylometazoline.Approved
CyclopenthiazideXylometazoline may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Xylometazoline.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Xylometazoline.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
DelaprilXylometazoline may increase the hypotensive activities of Delapril.Experimental
DeserpidineXylometazoline may increase the hypotensive activities of Deserpidine.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Xylometazoline.Approved
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Xylometazoline.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Xylometazoline.Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Xylometazoline.Experimental
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Xylometazoline.Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Xylometazoline.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Xylometazoline.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Xylometazoline.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Xylometazoline.Approved
DosulepinDosulepin may decrease the antihypertensive activities of Xylometazoline.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Xylometazoline.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Xylometazoline.Approved
DuloxetineDuloxetine may decrease the antihypertensive activities of Xylometazoline.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Xylometazoline.Approved
EfavirenzThe serum concentration of Xylometazoline can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Xylometazoline.Approved
EfonidipineXylometazoline may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
EnalaprilatXylometazoline may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Xylometazoline.Experimental
EpanololXylometazoline may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Xylometazoline.Approved
EprosartanEprosartan may increase the hypotensive activities of Xylometazoline.Approved
ErythromycinThe metabolism of Xylometazoline can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Xylometazoline.Investigational
EsmololXylometazoline may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
FelodipineFelodipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Xylometazoline.Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Xylometazoline.Experimental
Ferulic acidXylometazoline may increase the hypotensive activities of Ferulic acid.Experimental
FluconazoleThe serum concentration of Xylometazoline can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Xylometazoline.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Xylometazoline.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Fluvastatin.Approved
FosinoprilFosinopril may increase the hypotensive activities of Xylometazoline.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Xylometazoline.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Xylometazoline.Approved, Investigational, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Xylometazoline.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Xylometazoline.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Xylometazoline.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Xylometazoline.Approved
GuanazodineXylometazoline may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Xylometazoline.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
GuanoclorXylometazoline may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzXylometazoline may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanXylometazoline may increase the hypotensive activities of Guanoxan.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Xylometazoline.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Xylometazoline.Approved, Withdrawn
HarmalineHarmaline may increase the hypotensive activities of Xylometazoline.Experimental
HexamethoniumXylometazoline may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Xylometazoline.Approved, Investigational
HexobarbitalThe metabolism of Xylometazoline can be increased when combined with Hexobarbital.Approved
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Xylometazoline.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Xylometazoline.Experimental
HydralazineHydralazine may increase the hypotensive activities of Xylometazoline.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Xylometazoline.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
ImidaprilXylometazoline may increase the hypotensive activities of Imidapril.Investigational
ImipramineImipramine may decrease the antihypertensive activities of Xylometazoline.Approved
IndapamideIndapamide may increase the hypotensive activities of Xylometazoline.Approved
IndenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Xylometazoline.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Xylometazoline.Approved, Investigational
IprindoleIprindole may decrease the antihypertensive activities of Xylometazoline.Experimental
IproclozideIproclozide may increase the hypotensive activities of Xylometazoline.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Xylometazoline.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Xylometazoline.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Xylometazoline.Approved
IsradipineIsradipine may increase the hypotensive activities of Xylometazoline.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Xylometazoline.Approved, Investigational
JosamycinThe metabolism of Xylometazoline can be decreased when combined with Josamycin.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of Xylometazoline.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Xylometazoline.Approved, Investigational
KitasamycinThe metabolism of Xylometazoline can be decreased when combined with Kitasamycin.Experimental
LabetalolXylometazoline may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LacidipineXylometazoline may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololXylometazoline may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Xylometazoline.Approved
LinsidomineXylometazoline may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LofepramineLofepramine may decrease the antihypertensive activities of Xylometazoline.Experimental
LofexidineLofexidine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Xylometazoline.Approved
LovastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Lovastatin.Approved, Investigational
MacitentanXylometazoline may increase the hypotensive activities of Macitentan.Approved
Magnesium HydroxideThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineXylometazoline may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Xylometazoline.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Xylometazoline.Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Xylometazoline.Experimental
MepindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MethohexitalThe metabolism of Xylometazoline can be increased when combined with Methohexital.Approved
MethoserpidineXylometazoline may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Xylometazoline.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Xylometazoline.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
MethylphenobarbitalThe metabolism of Xylometazoline can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Xylometazoline.Approved
MetolazoneMetolazone may increase the hypotensive activities of Xylometazoline.Approved
MetoprololXylometazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineXylometazoline may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Xylometazoline.Experimental
MianserinThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilMibefradil may increase the hypotensive activities of Xylometazoline.Investigational, Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Xylometazoline.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Xylometazoline.Approved, Investigational, Vet Approved
MilnacipranMilnacipran may decrease the antihypertensive activities of Xylometazoline.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Xylometazoline.Approved
MinaprineMinaprine may increase the hypotensive activities of Xylometazoline.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Xylometazoline.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Xylometazoline.Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Xylometazoline.Approved
MivacuriumXylometazoline may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Xylometazoline.Approved
MoexiprilMoexipril may increase the hypotensive activities of Xylometazoline.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Xylometazoline.Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
MuzolimineXylometazoline may increase the hypotensive activities of Muzolimine.Experimental
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Xylometazoline.Experimental
NadololXylometazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NafcillinThe metabolism of Xylometazoline can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Xylometazoline.Approved
NaftopidilXylometazoline may increase the hypotensive activities of Naftopidil.Investigational
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Xylometazoline.Approved
NebivololXylometazoline may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Xylometazoline.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Xylometazoline.Approved
NicorandilXylometazoline may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Xylometazoline.Experimental
NiguldipineXylometazoline may increase the hypotensive activities of Niguldipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Xylometazoline.Investigational
NilvadipineXylometazoline may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Xylometazoline.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Xylometazoline.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
NitroprussideXylometazoline may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Xylometazoline.Approved
NortriptylineNortriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Xylometazoline.Approved, Vet Approved
ObinutuzumabXylometazoline may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Xylometazoline.Withdrawn
OleandomycinThe metabolism of Xylometazoline can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Xylometazoline.Investigational
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Xylometazoline.Experimental
OpipramolOpipramol may decrease the antihypertensive activities of Xylometazoline.Investigational
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Xylometazoline.Approved
OxprenololXylometazoline may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Xylometazoline.Investigational
PargylinePargyline may increase the hypotensive activities of Xylometazoline.Approved
PenbutololXylometazoline may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Xylometazoline.Approved
PentobarbitalThe metabolism of Xylometazoline can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Xylometazoline.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Xylometazoline.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Xylometazoline.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Xylometazoline.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Xylometazoline.Withdrawn
PhenobarbitalThe metabolism of Xylometazoline can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Xylometazoline.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Xylometazoline.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Xylometazoline.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Xylometazoline.Approved, Vet Approved
PinacidilPinacidil may increase the hypotensive activities of Xylometazoline.Withdrawn
PindololXylometazoline may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PirlindolePirlindole may increase the hypotensive activities of Xylometazoline.Approved
PitavastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Pitavastatin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Xylometazoline.Withdrawn
Platelet Activating FactorXylometazoline may increase the atrioventricular blocking (AV block) activities of Platelet Activating Factor.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Xylometazoline.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Xylometazoline.Approved, Investigational, Vet Approved
PractololXylometazoline may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PravastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Xylometazoline.Approved
PrimidoneThe metabolism of Xylometazoline can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Xylometazoline.Approved
PropranololXylometazoline may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Xylometazoline.Experimental
QuinaprilQuinapril may increase the hypotensive activities of Xylometazoline.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Xylometazoline.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Xylometazoline.Experimental
RamiprilRamipril may increase the hypotensive activities of Xylometazoline.Approved
RapacuroniumXylometazoline may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Xylometazoline.Approved
RemikirenRemikiren may increase the hypotensive activities of Xylometazoline.Approved
RescinnamineXylometazoline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Xylometazoline.Approved, Investigational
RifabutinThe serum concentration of Xylometazoline can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Xylometazoline can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Xylometazoline can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Xylometazoline can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Xylometazoline.Investigational
RiociguatXylometazoline may increase the hypotensive activities of Riociguat.Approved
RituximabXylometazoline may increase the hypotensive activities of Rituximab.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Rosuvastatin.Approved
SafrazineSafrazine may increase the hypotensive activities of Xylometazoline.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Xylometazoline.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Xylometazoline.Approved, Vet Approved
SaprisartanSaprisartan may increase the hypotensive activities of Xylometazoline.Experimental
SecobarbitalThe metabolism of Xylometazoline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Xylometazoline.Approved, Investigational, Vet Approved
SelexipagXylometazoline may increase the hypotensive activities of Selexipag.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Xylometazoline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
SilodosinSilodosin may increase the hypotensive activities of Xylometazoline.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Xylometazoline.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Xylometazoline.Approved, Investigational
SitaxentanXylometazoline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolithromycinThe metabolism of Xylometazoline can be decreased when combined with Solithromycin.Investigational
SotalolXylometazoline may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Xylometazoline.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Xylometazoline.Approved
TadalafilTadalafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
TalinololXylometazoline may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Xylometazoline.Approved
TelithromycinThe metabolism of Xylometazoline can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TemocaprilXylometazoline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the hypotensive activities of Xylometazoline.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Xylometazoline.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Xylometazoline.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TertatololXylometazoline may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrahydropalmatineXylometazoline may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineXylometazoline may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThe metabolism of Xylometazoline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Xylometazoline can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Xylometazoline.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
TiboloneXylometazoline may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Xylometazoline.Withdrawn
TimololXylometazoline may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Xylometazoline.Approved
TolazolineTolazoline may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Xylometazoline.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Xylometazoline.Approved, Vet Approved
TolonidineXylometazoline may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Xylometazoline.Approved
TorasemideTorasemide may increase the hypotensive activities of Xylometazoline.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Xylometazoline.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Xylometazoline.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Xylometazoline.Approved
TravoprostTravoprost may increase the hypotensive activities of Xylometazoline.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Xylometazoline.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Xylometazoline.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Xylometazoline.Approved, Investigational
TrimipramineTrimipramine may decrease the antihypertensive activities of Xylometazoline.Approved
TylosinThe metabolism of Xylometazoline can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Xylometazoline is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Xylometazoline.Approved, Investigational
UnoprostoneXylometazoline may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Xylometazoline.Investigational
ValsartanValsartan may increase the hypotensive activities of Xylometazoline.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Xylometazoline.Approved
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Xylometazoline.Approved
VincamineXylometazoline may increase the hypotensive activities of Vincamine.Experimental
VinpocetineXylometazoline may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Xylometazoline.Approved, Investigational
XipamideXylometazoline may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Xylometazoline.Approved, Vet Approved
ZofenoprilXylometazoline may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
External Links
Human Metabolome Database
HMDB15640
KEGG Compound
C07913
PubChem Compound
5709
PubChem Substance
99443248
ChemSpider
5507
BindingDB
30703
ChEBI
10082
ChEMBL
CHEMBL312448
PharmGKB
PA165958368
IUPHAR
517
Guide to Pharmacology
GtP Drug Page
Wikipedia
Xylometazoline
ATC Codes
S01GA53 — Xylometazoline, combinationsR01AB06 — XylometazolineS01GA03 — XylometazolineR01AA07 — Xylometazoline
AHFS Codes
  • 04:00.00 — Antihistamine Drugs
  • 52:32.00 — Vasoconstrictors

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAcute Rhinitis1
4CompletedTreatmentFlexible Nasendoscopy1
4CompletedTreatmentObstructive Sleep Apnea Syndrome (OSAS) / Rhinitis1
Not AvailableCompletedNot AvailableAcute Rhinitis1
Not AvailableCompletedTreatmentBronchiolitis1
Not AvailableRecruitingDiagnosticNasal Obstruction / Obstructive Sleep Apnea (OSA)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SprayNasal.01 L/L
SprayNasal10 mg/10mL
SprayNasal.05 mg/10mL
SolutionNasal0.1 %
SprayNasal0.1 %
Solution; sprayNasal0.1 %
Solution; sprayNasal.1 %
SprayNasal.1 %
Solution / dropsNasal0.1 %
Solution / dropsOphthalmic
SprayNasal0.05 %
Solution / dropsNasal0.05 %
Liquid; sprayNasal.1 %
Solution / dropsNasal.05 %
SprayNasal.05 %
SprayNasal.015 mL/15mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)132 °CPhysProp
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00893 mg/mLALOGPS
logP4.68ALOGPS
logP3.78ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)10.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area24.39 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity77.82 m3·mol-1ChemAxon
Polarizability29.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9866
Blood Brain Barrier+0.7293
Caco-2 permeable-0.5133
P-glycoprotein substrateSubstrate0.8254
P-glycoprotein inhibitor INon-inhibitor0.7469
P-glycoprotein inhibitor IINon-inhibitor0.8244
Renal organic cation transporterInhibitor0.6924
CYP450 2C9 substrateNon-substrate0.7815
CYP450 2D6 substrateNon-substrate0.531
CYP450 3A4 substrateNon-substrate0.5755
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9031
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9147
Ames testNon AMES toxic0.8306
CarcinogenicityNon-carcinogens0.9124
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1884 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9218
hERG inhibition (predictor II)Non-inhibitor0.745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-c862fcdd09df2d7e84e1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0090000000-8a168e444e92aebe729e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0190000000-fea379e1a78158c80c57
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0002-0490000000-f84be52191db834c336a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01s2-1950000000-6ff7d495e9ab66e5291e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01ta-1920000000-4fa30a0ba8151f6081f3

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
m-Xylenes / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylpropane / M-xylene / Xylene / Imidolactam / 2-imidazoline / Amidine / Carboxylic acid amidine / Azacycle / Organoheterocyclic compound / Organic 1,3-dipolar compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
alkylbenzene (CHEBI:10082)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91. [PubMed:8894610]
  2. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
  2. Petrusewicz J, Kaliszan R: Effect of imidazoline drugs on human blood platelet aggregation. Thromb Haemost. 1985 Dec 17;54(4):784-7. [PubMed:2868542]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]

Drug created on April 25, 2010 17:54 / Updated on January 14, 2018 10:04